関連する実験動画

Updated: May 19, 2026

Nanosponge Tunability in Size and Crosslinking Density
11:15

Nanosponge Tunability in Size and Crosslinking Density

Published on: August 4, 2017

合成ポリマーナノ粒子のタンパク質結合キネティクスの制御は,ポリマー鎖の柔軟性を調節し,形状の変化を誘導することによって行われる

Yu Hoshino1, Masahiko Nakamoto, Yoshiko Miura

  • 1Department of Chemical Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan. yhoshino@chem-eng.kyushu-u.ac.jp

Journal of the American Chemical Society
|September 6, 2012
PubMed
まとめ

研究者らは,タンパク質結合運動を制御するために,温度反応性ポリマーナノ粒子 (NP) を開発した. この酵素模倣戦略により,個別化された結合親和性が得られ,プラスチック抗体などの用途のために安定したNPタンパク質複合体が生成されます.

さらに関連する動画

OaAEP1-Mediated Enzymatic Synthesis and Immobilization of Polymerized Protein for Single-Molecule Force Spectroscopy08:34

OaAEP1-Mediated Enzymatic Synthesis and Immobilization of Polymerized Protein for Single-Molecule Force Spectroscopy

Published on: February 5, 2020

Combinatorial Synthesis of and High-throughput Protein Release from Polymer Film and Nanoparticle Libraries10:58

Combinatorial Synthesis of and High-throughput Protein Release from Polymer Film and Nanoparticle Libraries

Published on: September 6, 2012

関連する概念動画

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...